Mineralys Therapeutics, Inc.'s lorundrostat shows promise for treating aldosterone-driven hypertension with FDA approval by ...

Lorundrostat is an oral aldosterone synthase inhibitor targeting the treatment of hypertension, obstructive sleep apnoea, and ...

Mineralys Therapeutics (MLYS) announced detailed results from the pivotal Phase 3 Launch-HTN trial in over 1,000 participants ...

Mineralys Therapeutics’ hypertension drug candidate could offer a new treatment option for patients who don’t adequately respond to currently available blood pressure medicines. The once-daily ...

Mineralys expects to announce top-line data from the Explore-CKD trial later in the current quarter. The Chief Executive Officer confirmed the company's intention to submit an NDA for lorundrostat ...

M.D., Chief Medical Officer for Mineralys. "We believe this trial confirms the link between obesity, excess aldosterone production and hypertension. Based on the beneficial response observed in ...

The last time I wrote about Mineralys Therapeutics (NASDAQ:MLYS) it was with respect to a Seeking Alpha article entitled "Mineralys: 2nd Half 2024 Hypertension Data Readout". In this article ...

Mineralys Therapeutics, Inc. RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines ...

Mineralys Therapeutics is working on a treatment for patients with uncontrolled hypertension. New York veterinary operator opens Main Line clinic © 2025 American ...

Mineralys Therapeutics on Monday reported positive topline results from a pair of pivotal studies of its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension.

Mineralys Therapeutics launches $250 million stock offering Open in App ...

March 10 (Reuters) - Mineralys Therapeutics (MLYS.O), opens new tab said on Monday its lead drug significantly lowered blood pressure in patients with difficult-to-treat hypertension in late- and ...